Cellectar Biosciences (CLRB) Q2 FY26 earnings call

Cellectar Biosciences is entering a transformational period, driven by significant clinical and regulatory progress for Iopopacin I-131 in Waldenstrom's macroglobulinemia, targeting a mid-2027 NDA submission. The company also strengthened its financial position with an oversubscribed financing and is advancing its broader PDC platform with programs like CLR125 in TNBC. Management is focused on executing key milestones, including the initiation of the confirmatory Phase 3 study for Iopopacin and reporting initial data for CLR125.